- Home
- CISS vs CDIO Comparison
CISS vs CDIO Comparison
Compare CISS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | CDIO |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISS | CDIO |
|---|---|---|
| Price | $0.23 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 22.6K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | $15,782.00 |
| Revenue This Year | N/A | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | $2.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $2.42 |
| 52 Week High | $11.52 | $39.30 |
Technical Indicators
Market Signals| Indicator | CISS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 16.93 | 48.73 |
| Support Level | $0.20 | $2.80 |
| Resistance Level | $0.24 | $3.26 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 1.58 | 29.05 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.